International Evaluation of Research and Doctoral Training at the University of Helsinki 2005-2010: RC-Specific Evaluation of MS Group - Medication Safety Group by Saari, Seppo & Moilanen, Antti
  
Evaluation Panel: Medicine, Biomedicine and Health Sciences 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL 
TRAINING AT THE UNIVERSITY OF HELSINKI 2005–2010 
RC-Specific Evaluation of MS Group 
– Medication Safety Group 
Seppo Saari & Antti Moilanen (Eds.) 

  
  
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL 
TRAINING AT THE UNIVERSITY OF HELSINKI 2005–2010 
RC-Specific Evaluation of MS Group 
– Medication Safety Group 
Seppo Saari & Antti Moilanen (Eds.) 
University of Helsinki 
Administrative Publications 80/29 
Evaluations 
2012
  
 
 
 
Publisher: 
University of Helsinki 
Editors: 
Seppo Saari & Antti Moilanen 
Title: 
International Evaluation of Research and Doctoral Training at the University of 
Helsinki 2005–2010 : RC-Specific Evaluation of MS Group – Medication Safety 
Group 
Type of publication: 
Evaluations 
Summary: 
Researcher Community (RC) was a new concept of the participating unit in the evaluation. Participation 
in the evaluation was voluntary and the RCs had to choose one of the five characteristic categories to 
participate. 
Evaluation of the Researcher Community was based on the answers to the evaluation questions. In 
addition a list of publications and other activities were provided by the TUHAT system. The CWTS/Leiden 
University conducted analyses for 80 RCs and the Helsinki University Library for 66 RCs. 
Panellists, 49 and two special experts in five panels evaluated all the evaluation material as a whole and 
discussed the feedback for RC-specific reports in the panel meetings in Helsinki. The main part of this 
report is consisted of the feedback which is published as such in the report. 
Chapters in the report: 
1. Background for the evaluation 
2. Evaluation feedback for the Researcher Community 
3. List of publications 
4. List of activities 
5. Bibliometric analyses 
The level of the RCs’ success can be concluded from the written feedback together with the numeric 
evaluation of four evaluation questions and the category fitness. More conclusions of the success can be 
drawn based on the University-level report. 
RC-specific information: 
Main scientific field of research: 
Medicine, Biomedicine and Health Sciences 
 
Participation category: 
4. Research of the participating community 
represents an innovative opening 
 
RC’s responsible person: 
Airaksinen, Marja 
RC-specific keywords: 
patient safety, medication safety, medication 
management, collaborative practice, pharmaceutical 
services,  (medication-related) health technology 
assessment, effectiveness, cost-effectiveness, cost-
utility, pharmaceutical policy 
Keywords: 
Research Evaluation, Meta-evaluation, Doctoral Training, Bibliometric Analyses, Researcher Community 
Series title and number: 
University of Helsinki, Administrative Publications 80/29, Evaluations 
ISSN: 
1795-5513 (Online) 
ISBN:  
978-952-10-7449-3 (PDF) 
Total number of pages: 
70 
Language: 
English 
Additional information: 
Cover graphics: Päivi Talonpoika-Ukkonen 
Enquiries: seppo.o.saari@helsinki.fi 
Internet address: 
http://www.helsinki.fi/julkaisut/aineisto/rc_evaluation
2012/hallinnon_julkaisuja_80_29_2012.pdf 
 
 
 
 
 
Contents 
Panel members ........................................................................................................................... 1 
1 Introduction to the Evaluation ............................................................................................... 5 
1.1 RC-specific evaluation reports .......................................................................................................... 5 
1.2 Aims and objectives in the evaluation ............................................................................................... 5 
1.3 Evaluation method ............................................................................................................................ 5 
1.4 Implementation of the external evaluation ........................................................................................ 6 
1.5 Evaluation material ........................................................................................................................... 7 
1.6 Evaluation questions and material .................................................................................................... 8 
1.7 Evaluation criteria ........................................................................................................................... 10 
1.8 Timetable of the evaluation ............................................................................................................. 13 
1.9 Evaluation feedback – consensus of the entire panel ..................................................................... 13 
2 Evaluation feedback .............................................................................................................. 15 
2.1 Focus and quality of the RC’s research .......................................................................................... 15 
2.2 Practises and quality of doctoral training ........................................................................................ 15 
2.3 The societal impact of research and doctoral training ..................................................................... 16 
2.4 International and national (incl. intersectoral) research collaboration and researcher mobility ....... 17 
2.5 Operational conditions .................................................................................................................... 17 
2.6 Leadership and management in the researcher community ........................................................... 18 
2.7 External competitive funding of the RC ........................................................................................... 18 
2.8 The RC’s strategic action plan for 2011–2013 ................................................................................ 19 
2.9 Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) ......... 19 
2.10 Short description of how the RC members contributed the compilation of the stage 2 material ... 19 
2.11 How the UH’s focus areas are presented in the RC’s research .................................................... 19 
2.12 RC-specific main recommendations ............................................................................................. 19 
2.13 RC-specific conclusions ................................................................................................................ 20 
3 Appendices ............................................................................................................................ 21 
 
  
 
 
 
  
 
 
 
 
 
 
 
Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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Panel members 
CHAIR 
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Karolinska Institute, Sweden 
 
VICE-CHAIR 
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Molecular cell biology, cell adhesion, cancer biology 
University of Turku, VTT Technical Research Centre, Finland 
 
Professor Olli Lassila  
Immunology, medical microbiology 
University of Turku, Finland 
 
Professor Hans-Christian Pape 
Neuroscience, neurophysiology 
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The panel, independently, evaluated all the submitted material and was responsible for the 
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discussion and report writing. 
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providing the evaluation project with the updated information from TUHAT-RIS. 
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MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. She also assisted the UH/Library analyses. 
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
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Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
The special focus of the MS Group is in Health Care Sciences, particularly Medicines Management Services, 
and it integrates the disciplines of Social Pharmacy, Clinical Pharmacy and Pharmacoeconomics. The 
focused areas of research relate to the causes and effects of medication errors in Finland and establishing 
preventative mechanisms and guidelines to avoid such errors. Such studies require expertise in the above 
disciplines, with experienced scientists in these fields hard to recruit, and funding (from non-commercial 
sources to ensure impartiality) which again is difficult to source. 
The MS Group was formed relatively recently and operates under the Division of Social Pharmacy, 
Faculty of Pharmacy which was established in 2004. The RC is composed of 30 members with two 
professors and two acting professors. 
The RC has prioritized its key research areas as pharmaceutical policy research, medication safety, 
measuring effectiveness in pharmacoeconomical research and critical appraisal of evidence in drug 
therapy (systematic reviews and meta-analysis). Scientific work is oriented towards influencing 
professional practices and pharmaceutical policy making. The RC currently has 16 doctoral candidates with 
11 working outside the Faculty of Pharmacy. 
A major challenge for the RC is the fact that key journals in the field have low impact factors and 
publications in national journals, and since the work has high interest and need in Finnish society and 
policy making, it is appropriate to publish in domestic journals. Other outputs include contributions to 
policy documents and reports, and professional guidelines. As a consequence, the bibliometric analyses 
reflect these issues when judged on an international basis. There are 56 publications recorded, all with 
either national or international collaboration but impact value figures are as expected disappointing 
although three papers in the psychiatry discipline score high MNCS values. 
The ways to strengthen the activities are sound and progressive yet challenging, but the evidence 
indicates the group is determined and committed to raising the profile and standing of the RC and should 
be encouraged. 
Numeric evaluation: 3 (Very good) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
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 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
The RC follows the guidelines of the Faculty of Pharmacy and the Graduate School of Pharmaceutical 
Research for organising the doctoral training. Competitive recruitment is used for Faculty and Graduate 
School funded doctoral posts whilst others are recruited by professors for self-funded students. Doctoral 
research topics and study protocols and study plans (including plans for 60 ECTS credits) must fit the RC 
research areas and are designed in collaboration with supervisory teams who carefully monitor student 
progress and performance. A major challenge with this system is the coordinated supervision of external 
doctorate candidates, and it is recommended that the RC establishes guidelines to establish and ensure 
quality supervising for these candidates. One possible way to organize this would be to set up a thesis 
committee with regular meetings for all the enrolled students. An independent student network within the 
RC has been established to promote inter-team discussion, exchange of information, and to benefit from 
and share collective experience and learning. This represents a valuable and appropriate process for all 
members of the RC. 
The MS Group benefits from an extensive national and international cooperating network with external 
experts in the disciplines active in the RC, who have supported the research activities in general over the 
period of assessment as well as for the doctoral training acting as co-supervisors and pre-examiners. 
It is encouraging to note that the five PhD graduates during the assessment period found employment 
in their areas of study outside the University of Helsinki (UH), although with the limited access to 
experienced staff, mechanisms to access this alumni could be sought to help with this challenge. 
The major challenges identified for doctoral training are reported as being linked to increasing the 
domestic and international networks, securing additional resource of senior level staff and funding for 
doctoral training, although the actions being implemented to resolve these issues are not well articulated. 
Numeric evaluation: 3 (Very good) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The growing awareness of the importance of understanding the non-therapeutic impact of the use of 
medicines in society provides clear societal impact on the public, and thus highlights the stated aims of 
the MS Group both for Finland and on an international scale. Because of their specialised expertise, the RC 
staff are in high demand to serve on expert committees and working groups at home and abroad in the 
field of policy making in the delivery of services which provide safe, rational and cost effective medicines. 
Thus research findings from the RC have informed strategic planning decisions for the development of 
medication management services for the Finnish government and other agencies, a commendable 
achievement. 
The societal impact of the RC’s work, expertise and outputs, especially with its focus on Finland, is 
clear, and ways to strengthen this activity are described in detail. In their self-evaluation the RC 
emphasizes the need for European level data management and assessment of drug safety. However, it is 
not clear how the group aims to move into this direction in addition to their domestic efforts. However, 
the routes and mechanisms to be employed are not well described. 
Numeric evaluation: 3 (Very good) 
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2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The range of expertise available within the RC staff is providing opportunities for leadership nationally and 
to some extent internationally in the areas of growing and recognized importance – medication safety, 
pharmaceutical policy, pharmacoeconomics and clinical pharmacy. These disciplines form the core of the 
RC’s research programs. 
The RC has been involved with leading professional organizations in these fields (e.g. FIP, Global 
Research Institute for Pharmaceutical Practice) and organizing conference programs with similar agencies, 
as well as interacting with other research groups in these fields in the EU, Australia and New Zealand. 
These are all indicators of the growing strength and impact of the MS Group and the RC aims to expand 
these activities. It is important to promote international mobility also at the doctoral student and post-
doctoral level. Such plans have not been included in the evaluation material. 
The RC thus has a foundation in place upon which to build additional collaborations for research and 
doctoral training. However, due to the current situation of limited funding, resource and available time of 
staff, careful selection of key targeted interactions which will lead to an enhanced reputation and standing 
is recommended. Funding to support these ambitions remains a challenge and the leaders of the RC 
should explore all possible routes, including those beyond traditional sources, to secure additional finance 
and support. At the moment funding sources like the EU and different network programs for example have 
not been utilized. 
Numeric evaluation: 3 (Very good) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
As a relatively new group and RC, leadership and management procedures have been created and 
developed over the assessment period. With a small staff and consequential heavy teaching loads in the 
Faculty of Pharmacy, time available for research and supporting the postdoctoral students has been 
restricted. Additionally, limitations in infrastructure impose other burden on the staff. Nevertheless, efforts 
have been made to manage this difficult situation with responsibility and commitment. 
The actions proposed to deal with these challenges are consistent with previous arguments (see points 
1 – 4) and focus on recruiting additional senior research staff funded through increased external income. 
With the recognized and growing evidence of the values and societal impact of the work of the RC for 
the Faculty of Pharmacy, UH and the Finnish nation, the leaders may wish to consider preparing a 
comprehensive report articulating the specific and unique challenges faced by the RC and progress this 
document through appropriate channels of the UH in an attempt to secure additional resource. At the 
same time, all efforts should be made in securing additional external resource to support research and 
training budgets. 
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2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
For the MS Group, the establishment of leadership and management processes has taken much effort 
during the evaluation period, especially during the early years. All aspects of work and procedures have 
been reorganised with the goal to enable the formation of the research teams. Success has been 
demonstrated by the good progress made by these teams with internal structures in place to share 
research understanding and implications of policy and practice. Staff are highly motivated and committed. 
Whilst teaching loads are heavy, it is carefully planned around research objectives, and by optimising 
time allocation, motivation of staff is raised. 
The strength of the RC is seen as the close collaboration between all members of the research teams. 
The challenges which are detailed reflect well on the careful thought and analysis by the RC leaders, and 
are seen as prioritising the research projects and time allocations for teaching, and to invest more time 
and resource in sourcing external funding and long term strategic planning. The maintenance and 
development of the competencies of research staff via appropriate training and experience are also 
recognised as important for the strengthening and future success of the RC. 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
External grants have been secured for funding a professorial post in pharmacoeconomics (although it is 
not clear whether this is for a fixed time period) and €1.8m from the Ministry of Education for curriculum 
development and training in hospital pharmacy. 
Whilst these monies have helped to establish some foundations in research and training in the RC, 
additional resource is urgently required. As mentioned previously, the RC is recommended to engage in a 
major effort to search for other sources of external funding and prepare submissions. 
 
 
19 
 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
The RC correctly identifies that the way forward for the group is to build on current activities and 
successes, and create well funded and well resourced long term research projects in their targeted fields 
of study. This would deliver further understanding and provide trained experts in the field to meet 
growing national and international arenas. However, the initiatives to be undertaken and approaches to be 
undertaken to resolve these critical issues, especially the acquisition of funding, are not well presented or 
articulated. 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 4. The research of the participating community represents an innovative opening. 
 
The participation category selected by the RC is most appropriate – category 4. Whilst the research 
coupled to doctoral training has a special need in scientific, professional and societal sectors given the 
increasing awareness of medication errors and the need for studies in this area, it is thought that a more 
appropriate category, at this stage of development of the RC, would be participation category 2 ‘The 
research of the participating community is of high quality, but the community in its present composition 
has yet to achieve strong international recognition or a clear break-through’. It is not seen that the 
‘innovative opening’ detailed in the evaluation documentation provides a sufficient dimension of 
innovative new thinking and activity to justify category 4 membership. 
As highlighted in the comments above, the RC recognizes the need for additional resource as the major 
area for development, to provide opportunities for growing future success. However a clear description on 
how the RC plans to tackle this issue is not well described and articulated. 
Numeric evaluation: 3 (Very good) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
The process employed was fair and appropriate for preparing this document. 
2.11 How the UH’s focus areas are presented in the RC’s research 
The selected UH’s focus area 5 – ‘Welfare and safety’ – is appropriate for the topics of research and 
doctoral training for this RC. 
2.12 RC-specific main recommendations 
The Panel noted the strengths of the RC’s activities, including the societal impact of their work, in the field 
of medicine management and safety. The challenges faced by these relatively new areas of study within 
existing science based faculty structures, and ability to publish in high impact journals is recognized. The 
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efforts being made by the RC to seek solutions by conventional and alternative routes to overcome these 
issues is welcomed. Similarly the creation of appropriate practices and systems for quality training of 
doctoral students requires new approaches and again it is encouraging to note some positive and 
successful outcomes in this area. 
The Panel also recommend that attention is directed to address concerns raised by the RC on 
supervision of external doctoral candidates, perhaps via scheduled regular meetings of a thesis 
committee. 
Limitations to resource and funding are clearly constraining the activities of the RC. Given the clear 
commitment and dedication of the RC members, and the important societal role and impact of their work, 
the RC may wish to consider preparing a measured and strongly argued document to present to the UH via 
appropriate channels to request additional recognition of the RC and seek additional support. A parallel 
activity in searching widely for additional sources of external funds should also take place. 
The Panel considered the proposed assignment to research participation category 4 made by the RC, 
but following discussion, were of the opinion that a more appropriate categorization would be in 
participation category 2. 
2.13 RC-specific conclusions 
The Panel wishes to commend the RC for the progress they have made in initiating the research and 
teaching activities in the management and safety of medicines. The challenges faced by the RC, especially 
in resources, and in publishing in high impact journals, are recognized. 
The Panel suggests that a comprehensive document, detailing reasoned arguments and strategies to 
resolve these issues, is put forward to the UH for consideration and review. A parallel effort should also be 
initiated to seek all possible routes, conventional and alternatives, to enable the recruitment of new senior 
staff and additional doctoral students. 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
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NAME OF THE RESEARCHER COMMUNITY:  
Medication Safety Group (MS Group) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Prof. Marja Airaksinen, Division of Social Pharmacy, Faculty of Pharmacy 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
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(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Airaksinen, Marja 
E-mail:  
Phone: +358 50 3361203 
Affiliation: Division of Social Pharmacy, University of Helsinki 
Street address: Viikinkaari 9 C, 00014 University of Helsinki 
 
 
Name of the participating RC (max. 30 characters): Medication Safety Group 
Acronym for the participating RC (max. 10 characters): MS Group 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): The Division of Social 
Pharmacy at the University of Helsinki, established in 2004, has started a series of studies to identify service 
delivery processes and medicines associated with medication errors in the Finnish health care system. The 
goal is to apply this knowledge to develop preventive mechanisms and guidelines to avoid errors.  The work 
links to the  Council of Europe’s initiatives on patient safety and safe medication practices. Currently, this is 
the the Division’s key research area.  The goal is to assess how best to organize the service delivery and 
support services so that medicine use is safe, rational and cost-effective.  
The project operates at different levels of service development and outcomes assessment. The researcher 
community (Medication Safety Group, MS Group) has already performed extensive research at the 
patient/medicine user level. As a consequence, service delivery needs and the gaps between current 
services and patient needs in the Finnish context are quite well understood. The evidence indicates that the 
fundamental challenge is to reduce fragmentation and develop integrated services based on collaborative 
practice between different health care professionals and units. This integration also requires the 
involvement of patients/medicines users in their own care.   
The most urgent need is for drug information and patient education services, medication reviews, dose-
dispensing and monitoring services that are organized to assure a continuum of care with optimum 
outcomes. Our studies and experiences with work-life cooperation have shown that development and 
implementation of these kinds of services will require new support activities, including organizational 
culture and structure, and strategic resources.  The project is based on the scientific and practical 
experience of the researcher community and its intensive cooperation with international and national 
actors in coordinating medicines management services and technology. These relationships will facilitate 
application of the results. Altogether, the project involves 16 active Ph.D. students in different phases with 
their dissertation projects (+5 completed during 2005-2010). 
 
 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Health Care Sciences and Services 
RC's scientific subfield 2: Pharmacology and Pharmacy 
RC's scientific subfield 3: --Select-- 
RC's scientific subfield 4: --Select-- 
Other, if not in the list: Subfield 3: Social Pharmacy, Clinical Pharmacy and Pharmacoeconomics 
 
 
Participation category: 4. Research of the participating community represents an innovative opening 
Justification for the selected participation category (MAX. 2200 characters with spaces):  The MS Group’s 
research represents an innovative opening that combines research fields which have a special social, 
national and international priority.  Medications account for a high percentage of all events that can go 
wrong in health care. Consequently, adverse events due to medications have become a priority in health 
policy initiatives. Most of the evidence on medication errors and safe medication practices come from 
outside Europe, particularly from the US. There is an urgent need for creating evidence from European 
systems, including the Finnish system, and to give an overall perspective on medication safety both as a 
public health and as a health policy issue. Trends and interventions which are having a significant impact on 
improving medication safety, as well as strategies chosen in different countries, should be explored. In this 
respect, Pharmacy Practice, Clinical Pharmacy and Pharmacoeconomic research are needed to inform 
evidence-based policy.  
The long-term research strategy of the MS Group is influenced by national pharmaceutical policy goals and 
continuing research interests of the staff, especially its strong involvement in the national joint projects to 
improve medication management and integrate pharmaceutical services into other health care services. 
Research interests reflect training under a basic and graduate curriculum based on a systems approach and 
economic evaluation of practices.  The need for adding these areas to the Faculty of Pharmacy’s operations 
became evident from the external evaluation of the quality of education in 2001.   Subsequent milestones 
include the establishment of a Chair in Social Pharmacy in 2003 and one in Pharmacoeconomics in 2005, 
both donated by the University Pharmacy. Social Pharmacy became one of the divisions of the Faculty of 
Pharmacy in 2004. The Division has been actively involved in redesigning the pharmacy curriculum under 
the Bologna process. Subsequent changes include the establishment of new scientific studies for Master’s 
and doctoral students in Social Pharmacy and Pharmacoeconomics, and, since 2010, in Hospital Pharmacy. 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): 
Medicines play a key role in managing many major public health concerns. Even though drug therapies are 
evolving to be more effective and sophisticated, their actual impact on public health can vary and is 
dependent on the actual systems for medication use. Accumulating evidence of problems related to 
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managing medications in health care systems (such as errors, side-effects and medication interactions) 
suggest that little has actually been done to improve the process. Such improvements will require: new 
services, the adoption of technologies that prevent the occurrence of drug-related problems and 
medication errors, and developing methods to identify critical risk points in the medication use process.  
These have become leading issues internationally, and involve service delivery systems, technological 
innovation and adaptation of technology to new uses. 
The goal of this Researcher Community (Medication Safety Group) is to develop and implement new  
medication management services to improve drug therapy outcomes. It is a multidisciplinary effort 
employing collaborative practices and patient empowerment. The project is based on the researcher 
community’s scientific and practical experience in coordinating medication management services and 
technology and its long and intensive cooperation with international and national actors. These 
relationships will facilitate application of the results.     
The Medication Safety Group has several ongoing research projects concerned with developing medicines 
management services from different perspectives. The key is to assess how best to organize service delivery 
and support services so that medication use is safe, rational and cost-effective. Projects involve altogether 
16 active Ph.D. students in different phases with their dissertation projects (+ 5 completed). 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): The  MS Group’s research and development areas cover the applicant 
organization’s (Division of Social Pharmacy)  key strategic priorities and areas of excellence. The Group has 
made many contributions to strengthening  medication management in Finland. It has been involved in 
producing new practical innovations in patient service delivery and support activities, as well as strategic 
thinking that influences pharmaceutical policy, workforce development and the technological 
infrastructure. The research areas covered by the MS Group also have international relevance.  This work 
has added to scientific knowledge through publications in peer reviewed journals, contributions to working 
groups and congress programs, and personal contacts.     
The MS Group’s results have been utilized by bodies involved in strategic planning and those responsible 
for coordinating the development of medication management services, databases and information 
technology in Finland. These include a wide range of organizations within health care and pharmaceutical 
administration, such as authorities, professional organizations and continuing education units. The work 
will also benefit companies involved in providing information technology for medication management in 
health care.  Specifically, it will be of direct relevance to the University of Helsinki through the operations of 
the University Pharmacy and of the Palmenia Centre for Continuing Education. 
The MS Group has a wide cooperation network nationally and internationally. This network consists of  
scientists, educators, continuing education coordinators, pharmacy practitioners,  pedagogic and 
communication experts,  journal editor and drug and health policy makers.  This network of external 
experts has been crucial for starting the new discipline at the University of Helsinki and setting its strategic  
research and training goals.  
The MS Group has been actively involved in organizing professional and scientific programs for national and 
international audiences. The Group has contributed to committees and working groups concerning 
medication safety and health technology assessment (e.g. at the Ministry of Social Affairs and Health). 
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Keywords: patient safety, medication safety, medication management, collaborative practice, 
pharmaceutical services,  (medication-related) health technology assessment, effectiveness, cost-
effectiveness, cost-utility, pharmaceutical policy 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): Doctoral training in Social Pharmacy started 
at the University of Helsinki in 2003. Thus, the current evaluation period 2005-2010 covers the very first 
years of the discipline and scientific work initiated at the early phase of the operations.  There has been a 
lot of interest in having doctoral training in Social Pharmacy and Pharmacoeconomics which can be seen in 
the number of active Ph.D. students (currently 16, of whom 11 are working outside the faculty). In addition 
to work in progress, 5 Ph.D. candidates have completed during 2005-2010, which is quite a high number if 
taking into account the limited resources and the evolution phase of the discipline. Four of the current 
Ph.D. students are in the final phase of their work (expected to complete in 2011).  The limited resources 
concern particularly senior level scientists specialized in the field that could act as supervisors, and lack of 
external funding.  
The research funding has been mainly personal grants for Ph.D. students from non-profit sources. The 
researcher community’s principle has been to avoid commercial funding sources (e.g., drug companies) to 
avoid conflict of interest. This is important because the Group is cooperating with public sector 
stakeholders and those involved in pharmaceutical policy making. In the early phase of operations it has 
been necessary to allocate a lot of resources on development of competencies needed in scientific work  
(theory base and methodology). The Group has received 2 Fulbright grants for curriculum development in 
2007 and 2010.  
The Group has actively published in peer reviewed international journals that can be considered as main 
journals in the field with impact factors ranging between 1-3. The future goal is to publish in higher impact 
journals, such as BMJ (one paper currently under review). In addition to international fora, the Group 
actively publishes in national scientific and professional journals and contributes to policy documents and 
reports, and professional guidelines. More senior level scientists are needed in the team (e.g., via the 
adjunct professor system) and long-term research funding, particularly in Pharmacoeconomics and Hospital 
Pharmacy. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): The scientific work of the MS Group is strongly oriented towards influencing 
professional practices and pharmaceutical policy making. This can be seen in the publication strategy of the 
Group and outcomes of its scientific work. These aspects should be taken into account in the evaluation. It 
is also important to remember that the international and national scientific society in the field is limited 
which influences impact factors of the key journals.   
The Group’s Ph.D. candidates belong to the National Graduate School of Pharmaceutical Sciences. The 
graduate school is quite natural science oriented and does not provide as much support in theoretical and 
methodological studies for our students as for Ph.D. candidates from other disciplines involved. That is why 
the MS Group has organized an own Ph.D. student network which has regular research meetings (involves 
also supervisors). 
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Medication Safety Group
RC-LEADER M. Airaksinen
Category 4
Last name First name
Title of research and 
teaching personnel Affiliation 
1 Airaksinen Marja IV: Professor Faculty of Pharmacy, Division of Social Pharmacy
2 Blom Marja IV: Professor Faculty of Pharmacy, Division of Social Pharmacy
3 Aalto-Setälä Ville IV: Acting Professor Faculty of Pharmacy, Division of Social Pharmacy
4 Lyles Alan IV: Acting Professor Faculty of Pharmacy, Division of Social Pharmacy
5 Pohjanoksa-Mäntylä Marika
II: University Instructor, III: University 
Lecturer
Faculty of Pharmacy, Division of Social Pharmacy
6 Bell Simon III: University Lecturer Faculty of Pharmacy, Division of Social Pharmacy
7 Laaksonen Raisa III: University Lecturer Faculty of Pharmacy, Division of Social Pharmacy
8 Varunki Maaret II:University Instructor Faculty of Pharmacy, Division of Social Pharmacy
9 Pitkä Katja II: University Instructor Faculty of Pharmacy, Division of Social Pharmacy
10 Kärkkäinen Reijo II: University Instructor Faculty of Pharmacy, Division of Social Pharmacy
11 Linden-Lahti Carita
I: Doctoral Candidate, Education 
Planner
Faculty of Pharmacy, Division of Social Pharmacy
12 Kansanaho Heli I: Doctoral Candidate (completed) Faculty of Pharmacy, Division of Social Pharmacy
13 Alaranta Antti I: Doctoral Candidate (completed) Faculty of Pharmacy, Division of Social Pharmacy
14 Väänänen Minna I: Doctoral Candidate (completed) Faculty of Pharmacy, Division of Social Pharmacy
15 Aaltonen Elina II: University Instructor Faculty of Pharmacy, Division of Social Pharmacy
16 Aaltonen Kalle I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
17 Bulajeva Anna I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
18 Dimitrow Maarit I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
19 Holmström Anna-Riia I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
20 Koski Sari I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
21 Kurko Terhi I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
22 Leikola Saija I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
23 Mäenpää Timo I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
24 Parkkamäki Stiina I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
25 Passi Sanna I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
26 Sinnemäki Juha I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
27 Pietilä Kirsi III: University Lecturer Faculty of Pharmacy, Division of Social Pharmacy
28 Teinilä Tuula I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
29 Westerling Anna I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
30 Wiberg Ingrid I: Doctoral Candidate Faculty of Pharmacy, Division of Social Pharmacy
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Name of the RC’s responsible person: Airaksinen, Marja 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Medication Safety Group, MS Group 
The RC’s research represents the following key focus area of UH: 5. Hyvinvointi ja turvallisuus – Welfare 
and safety 
Comments for selecting/not selecting the key focus area: Medication Safety Group (MS Group) represents 
an innovative opening that combines research fields which have a special social, national and international 
priority. Pharmacotherapy plays a key role in managing many long-term diseases, but also minor symptoms 
in self-medication.  Medicines are used in various community and hospital settings. Their clinical, 
humanistic and economical value as a treatment method is highly influenced by appropriateness of use. 
Appropriateness of use covers professional practices, procedures, and systems, such as prescribing; order 
communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; 
administration; education; monitoring; and use. 
There is growing evidence that medications account for a high percentage of all events that can go wrong in 
health care. Consequently, prevention of adverse drug events has become a priority in health policy 
initiatives. In this respect, Medication Safety, Clinical Pharmacy and Pharmacoeconomic research are 
needed to inform evidence-based policy and practice development. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The RC's research focus  
The main scientific field of the RC is Medicine, Biomedicine and Health Sciences, with a special focus in 
Health Care Sciences and Services, particularly Medicines Management Services in different health care 
settings.  The RC integrates disciplines of Social Pharmacy, Clinical Pharmacy and Pharmacoeconomics.  
Social Pharmacy as a discipline evaluates non-pharmacological impact of medication use on society from 
the social science and economic perspective, raises discussion on problems related to the 
pharmaceutical sector, and promotes improvements in practice. Social pharmacy research also 
evaluates implemented changes to assess whether they led to desired outcomes in public health, and 
how the outcomes might be improved.  Clinical Pharmacy is an area of health sciences which focuses on 
optimizing medication use and preventing medication errors and drug-related problems by developing 
medication management systems and services. It is based on multidisciplinary collaboration and patient 
involvement in their own care in any settings where pharmacotherapy is part of patient care. 
Pharmacoeconomics is a discipline that analyzes the costs of medicines as they are used in society, 
health care systems and individuals and compares these costs to the outcomes of pharmacotherapy. 
 
The quality of the RC's research (incl. key research questions and results) 
The MS Group mainly operates under the Division of Social Pharmacy, Faculty of Pharmacy. The Division 
was established in 2004, a year after the first Professorship of the RC was established in 2003. The need 
for adding these areas to the Faculty of Pharmacy’s operations became evident from the international 
BACKGROUND INFORMATION 
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evaluation of education in 2001. Subsequent milestones include the establishment of a Chair in Social 
Pharmacy in 2003 and one in Pharmacoeconomics in 2005, both donated by the University Pharmacy.  
Since then, the RC has started a series of studies to identify service delivery processes and medicines 
associated with medication errors and drug-related problems in the Finnish health care system (Figure 
1). The goal is to apply this knowledge to develop preventive mechanisms to promote appropriate 
medication use and to avoid adverse drug events.  The work links to the Council of Europe initiatives on 
patient safety and safe medication practices. This is because the RC contributed to the preparation of 
Council of Europe recommendations in 2003-2006. Currently, medication safety and related 
pharmacoeconomical research are the key research areas of the Division of Social Pharmacy.  The goal is 
to assess how best to organize medication use and related service delivery and support systems so that 
medicine use is safe, rational and cost-effective. 
 
The RC’s projects operate at different levels of service development and outcomes assessment (Figure 
1). The RC has already performed extensive research at the patient/medicine user level. As a 
consequence, service delivery needs and the gaps between current services and patient needs in the 
Finnish context are quite well understood. The evidence indicates that the fundamental challenge is to 
reduce fragmentation and develop integrated services based on collaborative practices between 
different health care professionals and units. This integration requires involvement of 
patients/medicines users in their care. 
   
The most urgent need is for drug information and patient education services, medication reviews, dose-
dispensing and monitoring services that are organized to assure a continuum of care with optimum 
outcomes. Our studies and experiences of cooperation with people working in practice have shown that 
development and implementation of these kinds of services will require new support activities, including 
organizational culture and structure, and strategic resources. Currently, the research projects involve 3 
principal investigators (PIs), 3 Adjunct Professors and several senior level scientists outside the Division.  
RC has 16 active Ph.D. students in different phases with their dissertation projects (+5 completed during 
2005-2010). 
 
The RC has prioritized the following as its key research areas (May 2010): 
1) Research areas having a high societal need and impact 
- Pharmaceutical policy research (national and within European Union)  
- Medication safety (safety, effectiveness and cost-effectiveness of medication use processes; 
identification of high risk processes and medications; development and evaluation of mechanisms 
and services to prevent medication errors, such as medication reviews; drug information practices; 
development and evaluation of information technology for pharmaceutical services; patient 
involvement in their care; assuring and developing competencies needed in pharmaceutical 
practice and clinical pharmacy). 
 
2) New openings 
 - Measuring effectiveness in pharmacoeconomical research  
- Critical appraisal of evidence in drug therapy (systematic reviews and meta-analysis) 
  
The scientific significance of the RC's research for the research field(s). 
The RC represents a unique, but important research area.  The RC possesses scientific expertise that has   
great demand in different health care industries nationally and internationally, but is rarely available.  
This concerns both scientific evidence available and scientists capable applying research methodology 
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needed in producing sound evidence. E.g., the Professor of Pharmacoeconomics in our RC is the only 
Professor in that field in Finland and in the Nordic countries. Also clinical and hospital pharmacy is 
underdeveloped area of practice in health care, because of lack of research and training. As a 
consequence, most of the evidence on medication errors, safe medication practices and effectiveness of 
pharmaceutical interventions come from outside Europe, particularly from the US. There is an urgent 
need for creating evidence from European systems, including the Finnish system, and to give an overall 
perspective on medication safety both as a public health and as a health policy issue. Trends and 
interventions which are having a significant impact on improving medication safety, as well as strategies 
chosen in different countries, should be explored. In this respect, research and doctoral training of the 
RC has high societal demand and impact which range from product and service providers (e.g., drug 
industry, hospitals and community pharmacies) to policy-makers.    
The scientific work of the RC is strongly oriented towards influencing professional practices and 
pharmaceutical policy making. This can be seen in the publication strategy of the Group and outcomes 
of its scientific work. The Group has actively published in peer reviewed international journals that can 
be considered as key journals in the field with impact factors ranging between 1-5. The future goal is to 
publish in higher impact journals, such as the British Medical Journal (one paper currently under 
revision).  
Part of the scientific work has a high interest and need in the Finnish society and policy making, which 
make it relevant to publish such work in domestic scientific journals.  In addition to peer reviewed 
publications, the RC actively publishes in national professional journals and contributes to policy 
documents and reports, and professional guidelines. These aspects should be taken into account in the 
evaluation. It is also important to remember that the international and national scientific society in the 
field is limited which influences impact factors of the key journals and citation indexes that are possible 
to reach. 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
The RC has applied several strategies to strengthen the focus and improve the quality of research 
(ongoing):  
1)  Curriculum development for undergraduate and doctoral training since the RC establishment in 
2004.  The entire redesign includes new scientific studies for Master’s and doctoral students, and 
since 2010, specialization training in Hospital Pharmacy, all with special emphasis on research 
methodologies and theories. 
2)  The recruitment policy for key positions in the RC. We have succeeded to recruit some outstanding, 
research-oriented scientists from abroad and Finland who have remarkably contributed to the RC.  
Successful recruitment concerns also Master’s and doctoral students. 
3)  Intentional recruitment of Adjunct Professors with special expertise needed in RC to complement 
very limited number of senior scientists in the RC. 
4)  Active participation in international and national scientific and professional networks and 
organizations has remarkably influenced research orientation and competencies of the RC (both 
senior and junior members). 
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  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
How is doctoral training organised in the RC: General aspects  
RC’s doctoral training started in 2003. Thus, the evaluation period 2005-2010 covers the very first years 
of the doctoral training, and the scientific work initiated at the early phase of operations. There has 
been a lot of interest in having doctoral training in RC’s disciplines: the current number of active Ph.D. 
students is 16, of whom 11 are working outside the faculty.  In addition to work in progress, 5 Ph.D. 
candidates have completed during 2005-2010, which is quite a high number, if taking into account the 
limited resources and the evolving phase of the disciplines (e.g., the first permanent Chair in 
Pharmacoeconomics was appointed in December 2009; a more systematic research in hospital 
pharmacy was started in 2010 as a part of specialization training). Four of the current Ph.D. students are 
in the final phase (expected to complete in 2011).  The limited resources concern particularly senior 
level scientists that could act as supervisors, and lack of external funding for doctoral training.  
 
Describe the RC's principles for: 
Recruitment and selection of doctoral candidates. 
The RC belongs to the Faculty of Pharmacy and follows its guidelines for organizing doctoral training. 
The Faculty has reformed doctoral training practices to meet the guidelines given by the University in 
2006 as a part of the Bologna Process. The Faculty guidelines are integrated with those of the Graduate 
School in Pharmaceutical Research. The Graduate School selects doctoral students for funded positions 
through competitive recruitment (national procedure).  Otherwise, The Faculty does not have an official 
recruitment policy for doctoral students: each professor/PI can independently make their recruitments.      
 The RC has two doctoral student positions via the Faculty (governmental funding), and currently one 
through the Graduate School funding. These 3 doctoral students have been appointed through a 
competitive recruitment process. Others, with own funding have been recruited by the professors. 
These doctoral students come from working life. Some doctoral students have continued their Master’s 
thesis project to become a Ph.D. thesis. The criteria for recruitment is that the topic fits in the RC’s 
research areas and the applicant is capable of producing a study protocol and relevant theoretical study 
plan (60 ECTS credits) in collaboration with the professor and other supervisors. These documents need 
to be approved by the Vice Dean responsible for Scientific Affairs before the applicant is officially 
approved as a doctoral student (this policy has been effective since 2010, previously the Committee of 
Scientific Affairs approved the applications). The practice means that the applicants need to start close 
collaboration with the supervisors before applying for the training.    
 
Supervision of doctoral candidates 
All doctoral students have 1-2 senior level supervisors (professors/adjunct professors or PIs) and some 
junior RC members (e.g., recent Ph.D. graduates) involved in the supervision. Quite often the group also 
involves experts outside the RC.  Supervision follows principles of constructive learning and shared 
decision-making. This means that the supervisors need to be well-committed to the Ph.D. project. 
Therefore, it is important to have regular meetings throughout the project. The frequency of meetings 
varies according to phase of the project and need to be individually designed. Particularly important are 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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meetings in the beginning of the project to decide on the study protocol and theoretical studies that can 
support development of competencies needed in the research project. The supervisors’ task is to assure 
that the doctoral training includes a balanced mixture of substance and methodological studies and 
assures development of transferable skills needed in academic and scientific work.  The supervisors’ 
responsibility is also to involve the doctoral student in the RC (local and international).     
Most challenging is to organize supervision for doctoral students living outside the capital area. The 
ways we have tried to support their progress is intensive 1-2 day working sessions on data analysis and 
drafting manuscripts and their involvement in local university training.      
 
Collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
Since 2006, the RC’s doctoral students have belonged to the National Graduate School in 
Pharmaceutical Research (also in cases the training is not paid by the Graduate School). The graduate 
school is quite natural science oriented and does not provide as much support in theoretical and 
methodological studies for our students as for doctoral students from other pharmaceutical disciplines 
involved. That is why the MS Group has organized an own doctoral student network which has regular 
meetings (involves also supervisors). In the meetings, doctoral students present their study protocols, 
learn practical skills needed in research (e.g., preparing manuscripts for submission), and share current 
issues learnt in congresses and other scientific meetings.      
The RC has a wide cooperation network nationally and internationally. This network consists of 
scientists, educators, continuing education coordinators, pharmacy practitioners, pedagogic and 
communication experts, journal editor and drug and health policy makers.  This network of external 
experts has been crucial for starting the new discipline at the University and setting its strategic research 
and doctoral training goals.  Some of these experts have been involved as supervisors or unofficial 
mentors in doctoral training. The RC has received 2 Fulbright grants for curriculum development in 2007 
and 2010 (the latter will be used in spring 2011). These grants have facilitated development of 
competencies needed in scientific work (theory base and methodology) and long-term collaboration 
with senior scientists from highly ranked research units abroad, particularly in the USA, Australia and 
UK.  
 
Good practices and quality assurance in doctoral training 
The RC had a unique opportunity to benchmark best practices in doctoral training at the University of 
Helsinki through the involvement in the Doctoral Training Section of the Committee of Academic Affairs 
in 2007-2009.  We have found it important that the doctoral students first become acquainted with 
theoretical and methodological basis of their research area, and know previous research literature. They 
should network with actors and researchers in their field, and with the RC members, including other 
doctoral students. We have found it useful to involve doctoral students in different kinds of operations 
of the RC, such as creation of medication safety glossary in cooperation with the Center for 
Pharmacotherapy Development in 2005-2006, and involvement in Ministry of Health’s Steering Group 
on Patient Safety in 2007-2009.   It is also important to jointly prepare presentations for scientific 
congresses and introduce students to social networks there.    
To assure the quality of doctoral training, the RC has tried to select the best available experts and 
scientists from Finland and abroad for supervisors and pre-examiners.  
 
Assuring good career perspectives for the doctoral candidates/fresh doctorates. 
The University hardly has any career opportunities for Ph.D. graduates as postdoctoral or tenure track 
positions. Of the 5 Ph.D. graduates 3 have successfully continued their scientific work after completing 
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Ph.D. The reminder 2 is working in expert positions where they can apply their scientific knowledge. 
Career opportunities a 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
Strengths: 1) Regular meetings with supervisors throughout the Ph.D. project; 2) involvement of 
doctoral students in RC’s international and domestic scientific affairs; 3) regular doctoral student 
meetings; and 4) long-term collaboration with international experts involved in Ph.D. projects.  
Issues needing most improvement include: 
1)  More intensive networking nationally and internationally so that it will lead to actual research 
projects          
2)  More resources for doctoral students to take courses abroad in units with high quality research  
3)  Improving long-term funding for doctoral training, particularly in Hospital Pharmacy and 
Pharmacoeconomics. So far, funding has been mainly based on personal grants for doctoral students 
from non-profit sources.  
4)  Improving availability of training and consultation in research methodology (e.g., in statistics) 
5)  More senior level scientists are needed in the RC (preferably via the governmental funding, or via the 
adjunct professorship system) 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
As the main goal of the disciplines under the RC is to evaluate non-pharmacological impact of medicine 
use on the society from social science and economic perspective, this naturally puts high priority on 
interaction between the research and the society. Thus, a remarkable proportion of the time of the 
personnel is devoted to expert work in committees and working groups where decisions are being 
prepared or made concerning medicines in health care. The staff has been involved in national and 
international expert work in this respect. The key cooperative stakeholders nationally have been 
Ministry of Social Affairs and Health; National Institute for Health and Welfare;  Finnish Medicines 
Agency; National Center for Pharmacotherapy Development; Social Insurance Institution; National 
Supervisory Authority for Welfare and Health; Pharmaceutical Pricing Board; professional organizations 
(Association of Finnish Pharmacies, Finnish Pharmacists’ Association, Finnish Health Economists’ 
Society); and continuing education centers at the University of Helsinki and Eastern Finland, and 
Pharmaceutical Learning Center.  
Internationally the collaborators include Council of Europe; European Union; International 
Pharmaceutical Federation (FIP);  International Society of Pharmacoeconomics and Outcomes Research 
(ISPOR); EuroPharm Forum; European Association of Hospital Pharmacists, The Health Technology 
Assessment International, The International Health Economics Association, The Nordic Health 
Economists’ Study Group. 
The RC’s results have been utilized by bodies involved in strategic planning and those responsible for 
coordinating the development of medication management services, databases and information 
technology in Finland (most recently establishment of national pharmaceutical policy 2020 by the 
Ministry of Social Affairs and Health). These include a wide range of organizations within health care and 
pharmaceutical administration, such as authorities, professional organizations and continuing education 
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units. The work will also benefit those involved in providing information technology for medication 
management in health care.  Specifically, it will be of direct relevance to the University of Helsinki 
through the operations of the University Pharmacy and of the Palmenia Centre for Continuing 
Education. 
The  RC has made many initiatives and contributions to strengthening  medication management in 
Finland. It has been involved in producing new practical innovations in patient service delivery and 
support activities, as well as strategic thinking that influences pharmaceutical policy, workforce 
development and the technological infrastructure (see Figures 1 and 2). The most important of these 
innovative services are collaborative comprehensive medication reviews, medication information 
services, and tools to improve safe medication practices, particularly quality of geriatric 
pharmacotherapy. The research areas covered by the RC also have international relevance.  This work 
has added to scientific knowledge through publications in peer reviewed journals, contributions to 
working groups and congress programs, and personal contacts.     
The RC has a high public visibility which relates to research topics having practical implications in patient 
care. 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
The prerequisite for strengthening the societal impact of the RC’s research and doctoral training is that 
there will be more resources: 
1)  to increase methodological competencies in drug-related health technology assessment (HTA) both 
in the RC and in society. This requires resources for establishment of a curriculum, including training 
in outcomes assessment, critical appraisal of evidence (systematic reviews, meta analysis), modeling, 
register-based research and pharmacoepidemiology.  
2)  to assure sustained funding for specialization training in hospital pharmacy and related research 
(funding assured by the University of Helsinki by 2012). Research in this area is currently the most 
growing one in the RC, involving numerous hospitals and other health care institutions. It has 
potential for large scale networking with high societal impact through improving medication safety.  
3)  to increase research in pharmaceutical policy (national and within European Union). 
4)  to increase awareness of existing evidence produced by the RC. 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
Our RC has had unique opportunities for collaboration and benchmarking scientific practices of best 
units in our research area in different parts of the world.  Pharmacy practice research used to be the 
main research area of the RC in the beginning of the evaluation period. Since then, the research has 
moved its focus on medication safety, pharmaceutical policy, pharmacoeconomics, and most recently, 
on clinical pharmacy. The best research units have expertise in all these areas and integrate it in their 
research projects. In this respect, the development has been towards the right direction. Our RC has 
better understanding of pharmaceutical policy decision-making process and current topics under work 
than most of the collaborating and competing units. This reflects to selection of research topics, and 
thus, timeliness of research. These links to current policy making has opened new opportunities to be 
involved in decision making and bring our expertise e.g., to various working groups. 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
MOBILITY (MAX. 4400 CHARACTERS WITH SPACES) 
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Most crucial for scientific work and collaboration of the RC has been longstanding active involvement in 
the International Pharmaceutical Federation (FIP), which is a key professional organization covering all 
pharmaceutical sectors. It has provided an excellent platform for networking with key researchers in our 
field and collaborating with them.    
  
An important forum for research collaboration and benchmarking has been the GRIPP research network 
(Global Research Institute for Pharmacy Practice). The network was established and coordinated by the 
University of Sydney, Australia (established in 2005, our RC was one of the founding members). Other 
units that belong to the GRIPP are University of Copenhagen, University of Geneva/Lausanne, University 
of Lisbon, and University of Granada. The cooperation has been productive, particularly with the 
University of Sydney (e.g., student and researcher exchange and visits, recruitment of a Senior Lecturer 
in 2006).  Other collaborating universities include University of Bath, UK; Katholieke University of 
Leuven, Belgium; University of Groningen, The Netherlands; London School of Pharmacy, UK; University 
of Uppsala, Sweden; University of Malta; University of Tartu, Estonia; Monash University, Australia; and 
University of Otago, New Zealand.  
The RC has been regularly involved in organizing professional and scientific programs for national and 
international audiences (e.g., FIP Congress; International Social Pharmacy Workshop; European 
Conference in Health Economics; Nordic Social Pharmacy and Health Services Research Conference; 
Helsinki Drug Research Congress; Annual Meeting of Health Economics).  
Other benchmarking have been done through personal contacts, visits, student exchange, external 
evaluation of competencies of academic staff, opponent and jury memberships for Ph.D. candidates in 
several universities with advanced practices in disciplines covered by the unit.  One special contributor 
to mention is Prof. Alan Lyles from the University of Baltimore, USA. He has been involved in the RC 
since 2005, first by assisting in starting training and research in Pharmacoeconomics, then by providing 
his expertise to various research projects, mainly related to doctoral training (Adjunct Professor since 
2007). 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
The RC has excellent possibilities for national and international collaboration in research and doctoral 
training. The biggest challenge is to allocate time and resources for longstanding collaboration that will 
lead to actual projects, and thus, measurable productivity. Part of that is identification of the most 
important collaborators and concentrating working with them. Starting research projects requires 
usually site visits and personal meetings (at least 1-2 week’s visits to the collaborating unit or a 
visitor/visitors from there).    
As most of our important collaborators are geographically located far away from Helsinki (e.g., in the 
USA, Australia and Europe), it would be useful to develop new ways of communicating and collaborating 
with them. Information technology and distance education technology may provide fascinating 
opportunities in this respect. The RC has received funding for this purpose from the Fulbright Center in 
2010 (project will be started in spring 2011, involving first colleagues from Univ. of Baltimore and 
Sydney and Johns Hopkins Hospital). 
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 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
As the RC consists mainly of doctoral students they do not yet have much experience in conducting 
research and applying different kinds of methodologies. There is lack of senior researchers to mentor 
Ph.D. students and other junior level researchers. The small number of staff puts also limits to 
development of paradigm, coordination and delegation of the workload so that there would be more 
time for long-term planning of the research strategy and applying external funding.  So far, external 
funding has been marginal.  Part of the challenge that comes from limited resources is a heavy teaching 
workload to all academic staff, including doctoral students. Also, there is lack of availability of resources 
for postdoctoral training for recent Ph.D. graduates. In the long run, this jeopardizes availability of highly 
merited scientists in the academia who have specialized in research areas represented in the RC. This 
threat also concerns other institutions which need this kind of expertise (e.g., authorities, drug industry, 
health care organizations, professional organizations).   
The infrastructure of the Faculty of Pharmacy and the Viikki Campus does not provide optimum 
environment for research areas represented in the RC. This applies to multidisciplinary expertise needed 
in research methodology, statistics and statistical software, but also to environment where most of the 
research is conducted (different kinds of practice settings in health care). The research also requires 
expertise in clinical pharmacy and pharmacology, medicine and nursing sciences, health care 
management and policy, health economics, public health and epidemiology. As these disciplines are not 
strongly represented in undergraduate training it reflects to theoretical and methodological 
competencies of doctoral students.   
The most concrete deficiencies in the current infrastructure are that 1) the Faculty (and Viikki Campus) is 
missing statistician which reflects to competency of basic and doctoral students in statistics, and thus, 
quality of research, 2) the RC does not have administrative and technical support staff to assist in paper 
work related to teaching and research. Now this work needs to be mostly done by the academic staff of 
the division, including the senior staff. 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
To increase availability of senior scientists in the RC, there should be opportunities for recent Ph.D. 
graduates to have postdoctoral training. It should be possible to make at least part of the training 
abroad in collaborative units with best practices.    
There should be mechanisms at the faculty level to balance teaching workload of the units. Part of the 
solution is to assure availability of administrative staff to assist in administrative work related to 
teaching and research.   
Challenges related to the research environment can be partly compensated by extending collaboration 
with working life organizations (e.g., hospitals), professional organizations, authorities and research 
units within and outside the university. In this respect, we have started to involve scientists with clinical, 
medical and health economical expertise through adjunct professorships in our RC. 
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 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
Even though the RC was established quite recently in 2004, just before the current evaluation period, it 
has been productive in terms of peer-reviewed scientific papers in high or good impact factor journals, 
key domestic medical and pharmaceutical journals and in terms of other contributions based on its 
research. This has been possible by integrating research, teaching and activities towards society to 
become one entity, which optimizes use of very limited resources. This principle is in line with the 
strategic goal of the University for research-based teaching and societal impact. During the first years of 
operations, the RC has allocated resources for enhancing training in research methodology both at 
undergraduate and graduate levels which can be seen in quality of research. The wide national and 
international collaborative network has been used to compensate lack of senior level staff. The network 
also makes it possible to focus research to meet policy-making needs, and it provides continuous 
opportunities to reflect relevance and timeliness of the RC operations. 
Leadership is "organizing a group of people to achieve a common goal”. This has taken a lot of efforts 
during the evaluation period, particularly during the first years of operations. There has been need to 
organize and reorganize work and processes related to all aspects of academic work. The goal has been 
to support formation of research teams according to the key research areas of the RC. Each team has 
both senior and junior members and collaborators outside the RC.  Each team also has its special 
expertise in theories and methodologies. The goal is to integrate new research projects in these teams. 
This concerns also doctoral, Master’s and Bachelor’s  projects, and projects related to specialization 
training in hospital pharmacy.    
The RC is led according to principles of social constructivism and learning organization which mean 
shared decision-making and open disclosure of information with low hierarchy. Regular staff meetings 
have been important for organizing routines, processes and short term action plans. The RC has not yet 
established a long term strategic plan, because formation of the RC has been still going on (the goal is to 
get it done by the end of this year).   
During the last two years, the RC has made good progress in defining key research areas and finding 
shared understanding of theoretical and methodological foundation, as well as policy and practice 
implications of RC’s research (compare Figures 1 and 2). The RC members are highly motivated, goal-
oriented and committed to their work. They are innovative and supportive to new ideas and projects.      
Because of limited resources, all RC members participate in faculty administration. Everyone needs to 
take care of their responsibilities quite independently. Teaching duties are planned so that everyone can 
apply his/her special expertise. Teaching is also planned to serve research purposes which facilitates 
undergraduate students’ involvement in research activities of the RC.  This kind of integration optimizes 
RC members’ time allocation and increases motivation to teach. Doctoral students are involved in 
supervising Master’s thesis projects. All those projects are integrated in doctoral thesis projects 
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 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
The strength of the RC is close collaboration between PIs and other members of the research team 
which facilitates scientific dialogue and mentoring process between senior and junior researchers. Most 
challenging is to: 
1) Prioritize workload to allocate time for research. Prioritizing also concerns selection of research 
projects where the RC will contribute. 
2) Allocate more time for strategic long-term planning and applying external research funding. This 
particularly concerns PIs.        
3) Assure wellbeing and competencies of RC members, also continuity of contracts to facilitate long-
term commitment to research. Part of this is keeping up with the innovative working society that we 
have succeeded to create (this means having an awareness of unity on the part of all its members; 
having interpersonal relationships and chances to contribute; learn from and work with others; and 
having the ability to act together toward a common goal). We have had external coaching during 2010-
2011 for reaching these goals and improving practices and competencies in the RC. 
 
 
 
 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010:  
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010:  
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010:  
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010:  
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations:  
- total amount of funding (in euros) from the above-mentioned foundations:  
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations:  
- total amount of funding (in euros) from the above-mentioned funding organizations:  
 
7 EXTERNAL COMPETITIVE FUNDING OF THE RC 
 12 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 2 MATERIAL  
 
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: University Pharmacy, donation for Professorship in 
Pharmacoeconomics in 2005 
- Ministry of Education, Curriculum development in hospital pharmacy training in 2009 
- total amount of funding (in euros) from the above-mentioned funding organizations: 1600000 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
Crucial for the future success and development of the RC is external funding that could facilitate long-
term research in selected key areas. It is also important to strengthen integration between key research 
areas in medication safety, hospital pharmacy, and pharmacoeconomical research to assure optimum 
use of limited resources. These disciplines benefit of collaboration, still, each of them have its own 
specialities which should be respected in the RC’s operations.   
The RC has created a good potential for large-scale research programs that could be funded by external 
funding.  To realize this potential, the RC should develop a long-term strategic research plan, including a 
thorough inventory of possible funding sources. The long-term research strategy of the RC should be 
influenced by national pharmaceutical policy goals and continuing research interests of the staff, 
especially its strong involvement in the national joint projects to improve medication management and 
integrate pharmaceutical services into other health care services. Research interests should reflect 
training under a basic and graduate curriculum based on a systems approach and economic evaluation 
of drug therapies and practices.  
Future success of the RC is highly dependent on human resources. The RC needs more senior scientists 
that have competencies in various research methodologies, statistics, clinical practice and health 
management sciences.  There is also need for having more opportunities for doctoral training through 
the Graduate School in Pharmaceutical Research. Both Pharmacoeconomics and Hospital Pharmacy are 
currently lacking such opportunities, although there is a growing need for specialized scientists in these 
fields.  Part of creating human resources is providing opportunities for recent Ph.D. graduates to 
continue their research in academia and have postdoctoral training abroad in highly ranked research 
units. Intensive international collaboration is essential because the national RC is small and still in an 
early phase of development.   
There is a growing need for evidence and expertise produced by the RC within all sectors in 
pharmaceutical field, but also in health care in a broader perspective. More and more of the research 
collaboration have been directed outside traditional pharmaceutical sector. The research projects 
initiated in key research areas have evolved to the point that they could be potential for external 
funding. Also the collaborators in these projects belong to the national top in their fields (e.g., in health 
technology assessment, medication safety and pharmaceutical policy). Likewise, the projects involve 
highly esteemed international experts.          
There has been a lot of interest to start Ph.D. studies in disciplines under social pharmacy. This means a 
big potential of competent experts who could bring their expertise and practical experience to the 
discipline and produce new knowledge on the role and function of medicines in health care.  As the unit 
is physically closely located to headquarters of many national stakeholders in health care and 
pharmaceutical sector it makes cooperation feasible. In addition to start joint research projects with 
8 RC’S STRATEGIC ACTION PLAN FOR 2011–2013 (MAX. 4400 CHARACTERS WITH SPACES) 
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international colleagues, there are also opportunities to recruit international experts to the staff, e.g., as 
scholars or postdoctoral scientists, and thus, diversify the knowledgebase of the division.   
Threats: Failure in applying external funding; failure in getting new vacancies through the university to 
have more staff; failure in cooperation and coordination of research so that it would lead to concrete 
research projects that can be completed and reported in scientific literature. Failure in establishing 
umbrella headline and long-term strategy for the research. Failure in recruiting competent staff. 
 
 
 
Each RC member has participated in entering data in the TUHAT database. This project has been 
regularly discussed in staff meetings and it has been under progress since spring 2010.   
The RC defined its key research areas in spring 2010. It was quite easy to agree on them as the key 
research areas have been discussed in research planning meetings and the RC has followed certain 
research lines since its establishment (+ the new research lines that were easy to identify). The RC 
created a 5-year report on its operations in 2009 which was useful for sharing understanding of RC’s 
scientific work and its theoretical basis. The RC has continued its work on action reports: each research 
team is currently processing its own report which assists each team to clarify its research questions, 
objectives, theory base, methodology and key findings, including policy and practice implications of the 
research.        
Research issues have been discussed in staff meetings and in the coaching process to develop academic 
leadership of the RC (a pilot project of the  Rector’s Office to develop a procedure 
9 SHORT DESCRIPTION OF HOW THE RC MEMBERS HAVE CONTRIBUTED TO THE COMPILATION OF THE STAGE 2 
MATERIALS (MAX. 1100 CHARACTERS WITH SPACES). 
Developing Medicines Management Services & Technology in Finnish Health Care:
A Systems Approach Integrating Efficiency, Safety and Effectiveness
PATIENTS
Technologies
Administrative Systems
Applied Communication Research
& Training
Curriculum Redesign
Continuing Education
Project # 1, # 2
Project # 5
Project # 4 Project # 3
Project # 6
Project # 7
Figure 1. Theoretical framework of the MS Group’s research as a medicines management
system modified from Kaplan & Norton (2000)1.  The figure also shows the points of the
system covered by seven Ph.D. research projects included in the application (Projects 1-7).
1Source: Swayne, Duncan and Ginter. Strategic Management of Health Care Organizations, 5th edition. Blackwell Publishers. Malden,
Massachusetts, 2006. ISBN 1-4051-2432-6
Outcomes Variation from Efficacy to Effectiveness
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Figure 2. Benefits of the MS Group’s  research at different levels of the medicines
management system (constructed by Dr. Lyles, 2008)
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1 Analysis of publications 
 
- Associated person is one of Marja Sisko Anneli Airaksinen ,  Marja Blom ,  Ville Aalto-Setälä, Marika Pohjanoksa-
Mäntylä ,  Simon Bell ,  Raisa Laaksonen ,  Maaret Mira Varunki , 
Katja Pitkä ,  Reijo Kärkkäinen ,  Carita Linden-Lahti ,  Heli 
Kansanaho, Antti Alaranta ,  Minna Väänänen , Kalle Jyri Mikael Aaltonen , Maarit 
Dimitrow, Anna-Riia Holmström , Sari Koski ,  Terhi Kurko ,  Saija Leikola , 
Stiina Parkkamäki ,  Sanna Passi ,  Juha Matias Sinnemäki , 
Kirsi Pietilä, Tuula Teinilä ,  Anna Westerling ,  
 
                    Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 11 20 17 14 23 14 99 
A2 Review in scientific journal   1 1 1  3 
A3 Contribution to book/other compilations (refereed) 4  1 1 1  7 
A4 Article in conference publication (refereed) 4   1   5 
B1 Unrefereed journal article 5 5 5  2  17 
B2 Contribution to book/other compilations (non-refereed) 1 2     3 
C1 Published scientific monograph   1 1   2 
C2 Edited book, compilation, conference proceeding or special issue of 
journal 
1 1     2 
D1 Article in professional journal 1  1 2 1 3 8 
D2 Article in professional hand or guide book or in a professional data 
system, or text book material 
     1 1 
D4 Published development or research report   1 1  1 3 
D5 Text book or professional handbook or guidebook or dictionary 2  1    3 
E1 Popular article, newspaper article 1 1  3   5 
E2 Popular monograph     1  1 
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2 Listing of publications 
A1 Refereed journal article 
2005 
Hämeen-Anttila, K, Juvonen, M, Ahonen, R, Bush, PJ, Airaksinen, M 2005, 'What schoolchildren should be taught about medicines: 
combined opinions of children and teachers', Health Education. 
Kansanaho, H, Cordina, M, Puumalainen, I, Airaksinen, M 2005, 'Practicing pharmacists' patient counseling skills in the context of 
reflectivity', Pharmacy Education. 
Kansanaho, H, Puumalainen, I, Varunki, M, Ahonen, R, Airaksinen, M 2005, 'Implementation of a professional program in Finnish 
community pharmacies in 2000 - 2002', Patient Education and Counseling. 
Lamminen, S, Airaksinen, M 2005, 'Itsehoitovalmisteiden pakkausselosteiden luettavuus', Dosis, vol 21, no. 2, pp. 154-163. 
Puumalainen, I, Kansanaho, H, Varunki, M, Ahonen, R, Airaksinen, M 2005, 'Usefulness of the USP medication counselling behavior 
guidelines', Pharmacy World and Science. 
Puumalainen, I, Halonen, P, Enlund, H, Johnson, K, Airaksinen, M 2005, 'Validation of the United States Pharmacopeia (USP) 
medication counselling behaviour guidelines', Pharmacy Education. 
Puumalainen, I, Kause, J, Airaksinen, M 2005, 'Quality assurance instrument focusing on patient counseling',  Annals of 
Pharmacotherapy. 
Puumalainen, I, Peura, S, Kansanaho, H, Benrimoj, C, Airaksinen, M 2005, 'Progress in patient counselling practices in Finnish 
community pharmacies', International Journal of Pharmacy Practice. 
Pörhölä, O, Kuosa, T, Airaksinen, M, Varunki, M, Varunki, M 2005, 'Henkilökohtainen opintosuunnitelma (HOPS) apteekkiharjoittelussa', 
Dosis, vol 21, no. 4, pp. 266-273. 
Räsänen, P, Sintonen, H, Ryynänen, O, Blom, M, Semberg-Konttinen, V, Roine, RP 2005, 'Measuring cost-effectiveness of secondary 
health care: Feasibility and potential utilization of results', International Journal of Technology Assessment in Health Care, vol 21, 
no. 1, pp. 22-31. 
Toivo, T, Airaksinen, M, Laine, K, Kalsta, K, Mikkola, J 2005, 'Ovatko vakavat lääkeinteraktiot yleisiä avohoidon potilailla?', Suomen 
lääkärilehti , vol 60, no. 23, pp. 2600-2604. 
2006 
Alaranta, A, Alaranta, H, Heliövaara, M, Airaksinen, M, Helenius, I 2006, 'Ample use of physician-prescribed medications in Finnish elite 
athletes', International Journal of Sports Medicine. 
Alaranta, A, Alaranta, H, Holmila, J, Palmu, P, Pietilä, K, Helenius, I 2006, 'Self-reported attidutes of elite athletes towards doping: 
differences between type of sport', International Journal of Sports Medicine. 
Alaranta, A, Alaranta, H, Patja, K, Palmu, P, Prättälä, P, Martelin, T, Helenius, I  2006, 'Snuff use and smoking in Finnish olympic 
athletes', International Journal of Sports Medicine. 
Bell, JS, Johns, R, Rose, G, Chen, TF 2006, 'A Comparative study of consumer participation in mental health pharmacy education', 
Annals of Pharmacotherapy. 
Blom, M, Tuominen, U, Seitsalo, S, Malmivaara, A, Hirvonen, J, Hietaniemi, K, Lehto, M, Paavolainen, P, Sintonen, H, Rissanen, P 
2006, 'Lonkan ja polven tekonivelleikkaushoidon vaikuttavuus: satunnaistettu vertailututkimus nopeasti leikattujen ja ei-leikattujen 
(jonossa olevien) potilaiden välillä', Suomen ortopedia ja traumatologia., vol 29, no. 3, pp. 331-335. 
Gisev, N, Bell, JS, McLachlam, A, Chetty, M, Chen, T 2006, 'Psychiatric drug use among patients of a community mental health service: 
patterns and implications', Disease Management & Health Outcomes. 
Hautamäki, M, Hirvonen, J, Airaksinen, M 2006, 'Farmaseuttien työssä viihtyminen ja unelmatyöura', Dosis, vol 22, no. 3, pp. 193-204. 
Hautamäki, M, Hirvonen, J, Airaksinen, M 2006, 'Farmaseuttien sijoittuminen työelämään: koulutuksen ja työelämän vastaavuus', 
Dosis, vol 22, no. 3, pp. 183-192. 
Hirvonen, J, Blom, M, Tuominen, U 2006, 'Onko hoitopaikalla väliä?', Suomen lääkärilehti , vol 61, no. 3, 205-207 s. 
Hirvonen, J, Blom, M, Tuominen, U, Seitsalo, S, Lehto, M, Paavolainen, P, Hietaniemi, K, Rissanen, P, Sintonen, H  2006, 'Health-
related quality of life in patients waiting for major joint replacement: a comparison between patients and population controls',  Health and 
Quality of Life Outcomes, vol 4, no. 3, pp. ]. 
Hirvonen, J, Blom, M, Tuominen, U, Sintonen, H, WHJR Study Group 2006, 'The use of patient-reported outcomes (PROs) in patients 
who underwent major joint replacement and those who left the queue', Patient reported outcomes newsletter., no. 36, pp. 31-33. 
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Hämeen-Anttila, K, Juvonen, M, Ahonen, R, Bush, PJ, Airaksinen, M 2006, 'How well can children understand medicine related topics?', 
Patient Education and Counseling, vol 60, no. 2, pp. 171-178. 
Hämeen-Anttila, K, Airaksinen, M, Vainio, K, Bush, PJ, Ahonen, R 2006, 'Developing a medicine education program in Finland: Lessons 
learned', Health Policy. 
Hämeen-Anttila, K, Airaksinen, M, Bush, PJ, Ahonen, R 2006, 'Medicine education for schoolchildren: what do the teachers think?', 
Health Education. 
Räsänen, P, Öhman, J, Sintonen, H, Ryynänen, O, Koivisto, A, Blom, M, Roine, RP  2006, 'Cost-utility analysis of routine neurosurgical 
spinal surgery', Journal of neurosurgery: Spine, vol 5, no. 3, pp. 204-209. 
Räsänen, P, Krootila, K, Sintonen, H, Leivo, T, Koivisto, A, Ryynänen, O, Blom, M, Roine, RPA 2006, 'Cost-utility of routine cataract 
surgery', Health and Quality of Life Outcomes, vol 4, no. 74. 
Räsänen, P, Sintonen, H, Ryynänen, O, Blom, MLJ, Roine, R 2006, 'Comparing Cost-Utility of six common Surgical Procedures',  
European Journal of Health Economics, vol 7, no. S1, pp. S131. 
Tammimäki, A, Pietilä, K, Raattamaa, H, Ahtee, L 2006, 'Effect of quinpirole on striatal dopamine release and locomotor activity in 
nicotine-treated mice', European Journal of Pharmacology. 
Toivo, T, Airaksinen, M 2006, 'Lääkehoidon turvallisuutta ja potilasturvallisuutta kuvaava käsitteistö - lääkehoidon turvallisuussanaston 
kokoaminen', Dosis, vol 22, no. 4, pp. 329-346. 
Väänänen, M, Pietilä, K, Airaksinen, M 2006, 'Self-medication with antibiotics - Does it really happen in Europe?', Health Policy. 
2007 
Aalto-Setälä, V, Kanerva, R, Bell, S 2007, 'Drug cost development of citalopram and fluoxetine following the introduction of generic 
substitution in Finland', International journal of pharmaceutical medicine, vol 21, no. 5, pp. 363-368. 
Bell, S, Väänänen, M, Ovaskainen, H, Närhi, U, Airaksinen, M 2007, 'Providing patient care in community pharmacies: practice and 
research in Finland', Annals of Pharmacotherapy, vol 41, no. 6, pp. 1039-1046. 
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lääkehoidossa: moniammatillinen toimintatutkimus Tampereella',  Suomen lääkärilehti , vol 61, no. 14, pp. 1621-1625. 
Savikko, V, Teinilä, T, Airaksinen, M 2006, 'Erehtyminen on inhimillistä - selvitys apteekkien toimitusvirheistä', TABU : 
lääkeinformaatiota Lääkelaitokselta, vol 14, no. 4, pp. 4-7. 
Tuominen, U, Blom, M, Hirvonen, J, Seitsalo, S, Paavolainen, P, Lehto, MUK, Hietaniemi, K, Rissanen, P, Sintonen, H 2006, 'Millainen 
vaikutus lisäsairauksilla on lonkan tekonivelleikkaukseen jonottavien potilaiden elämänlaatuun?',  Suomen ortopedia ja traumatologia., 
vol 29, no. 3, pp. 354-357. 
2007 
Blom, M 2007, 'Uusia lääkkeitä koskevan informaation lähteet Kanadassa', Impakti : tietoa terveydenhuollon menetelmien 
arvioinnista, no. 5, pp. 6. 
Blom, M 2007, 'HTA -menetelmä innovatiivisille teknologioille Saksassa',  Impakti : tietoa terveydenhuollon menetelmien 
arvioinnista, no. 5, pp. 6. 
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Blom, M 2007, 'Nopeat arviot uusista lääkeistä helpottavat taloudellista suunnittelua Skotlannissa',  Impakti : tietoa terveydenhuollon 
menetelmien arvioinnista, no. 5, pp. 6-7. 
Blom, M 2007, 'Varhainen tunnistamisjärjestelmä Australiassa ja Uudessa-Seelannissa', Impakti : tietoa terveydenhuollon 
menetelmien arvioinnista, no. 5, pp. 7. 
Blom, M, Saalasti-Koskinen, U 2007, 'Näyttöä Wienin työpajoista', Impakti : tietoa terveydenhuollon menetelmien arvioinnista, no. 
6, pp. 6. 
2009 
Airaksinen, M, Bult, K, Sevon-Vilkman, N, Tuomainen, L 2009, 'How pharmacists update their professional skills and knowledge in 
Finland: development since the 1980s', Dosis, vol 25, no. 2, pp. 78-84. 
Ovaskainen, H, Forsberg, M, Nuutila, AM, Airaksinen, M 2009, '25 vuotta Dosista: päätoimittajien muistoja matkan varrelta', Dosis, vol 
25, no. 4, pp. 175-180. 
B2 Contribution to book/other compilations (non-refereed) 
2005 
Airaksinen, M 2005, 'Concordance: developing patient-centred practice in community pharmacies',  Phuture education supplement, 
Education supplement, vol. 12, IPFS, Hague, pp. 8-9. 
2006 
Kanerva, M, Lyytikäinen, O, Tuominen, U, Kolho, E, Anttila, V, Vaara, M, Virolainen-Julkunen, A, Agthe, N, Blom, M 2006, 'MRSA-
epidemian kustannusanalyysi Meilahden ja Töölön sairaaloissa 1.9.2003-31.10.2004',  MRSA-epidemian kustannusanalyysi 
Meilahden ja Töölön sairaaloissa 1.9.2003-31.10.2004. 
Tuominen, U, Hirvonen, J, Blom, M, Polkka-tutkimusryhmä, Sintonen, H, Rissanen, P, Hietaniemi, K, Lehto, MU, Paavolainen, P, 
Seitsalo, S 2006, 'Comorbiditeetin vaikutus lonkan tekonivelleikkaukseen jonottavien potilaiden elämänlaatuun', Terveystaloustiede 
2006, Stakes, Helsinki, pp. 54-57. 
C1 Published scientific monograph 
2007 
Airaksinen, M, Otero, M, Schmitt, E, Cousins, D, Gustafsen, I, Hartmann, M, Lyftingsmo, S, Muff, P, Thors, C, Vlcek, J, Expert Group on 
Safe Medication Practices 2007, Creation of a better medication safety culture in Europe: building up safe medication practices, 
Council of Europe, 260. 
2008 
Leipälä, J, Saalasti-Koskinen, U, Blom, M, Autti-Rämö, I, Gissler, M, Hämäläinen, E, Paganus, A, Isojärvi, J, Kääriäinen, H, Renlund, M, 
Mäkelä, M 2008, Fenylketonurian seulonta Suomessa, Finohtan julkaisuja, no. 1/2008, Stakes/Finohta, Helsinki. 
C2 Edited book, compilation, conference proceeding or special issue of journal 
2005 
Airaksinen, M (ed.) 2005, Programme and the Book of Abstracts: 2nd Nordic Social Pharmacy and Health Services Research 
Conference, November 10-11 2005, Lahti, Finland,  University of Helsinki, Helsinki. 
2006 
Outinen, M, Airaksinen, M (eds) 2006, Potilas- ja lääkehoidon turvallisuussanasto, Työpapereita / Stakes, no. 28/2006, Stakes, 
Helsinki. 
D1 Article in professional journal 
2005 
Airaksinen, M 2005, 'Suomi - Kliinisen farmasian kehitysmaa?', Proviisorilehti, vol 2005, no. 4, pp. 16-17. 
2007 
Westerling, A, Haikala, V, Airaksinen, MSA 2007, 'Toiveiden tynnyristä työkaluksi – Apteekin tietojärjestelmät kaipaavat kehittämistä',  
Apteekkari : Suomen apteekkarilehti, vol 2007, no. 3. 
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2008 
Kurko, T, Airaksinen, MSA 2008, 'Mielipide: Lääketeollisuuden apteekkeihin suuntautuvasta markkinointitoimepiteistä"', Apteekkari : 
Suomen apteekkarilehti, vol 2008, no. 3, pp. 25. 
Lyly, T, Pohjanheimo, S, Airaksinen, MSA, Linden, C 2008, 'Riskilääkkeiden käytön ohjeistus ja lääkitysvirheiden seuranta sairaaloissa',  
TABU : lääkeinformaatiota Lääkelaitokselta, vol 16, no. 2, pp. 11-15. 
2009 
Pohjanoksa-Mäntylä, M, Aaltonen, KJM, Holmström, A, Airaksinen, MSA 2009, 'Sosiaalifarmasian tutkimus Pohjoismaissa – vastauksia 
lääkehuollon haasteisiin?', Farmasia : Suomen farmasialiiton jäsenlehti, vol 91, no. 9, pp. 24-27. 
2010 
Pohjanoksa-Mäntylä, M, Varunki, M 2010, '”Internet – se on vaan sellainen lisämauste toistaiseksi”', Farmasia : Suomen 
farmasialiiton jäsenlehti, vol 92, no. 6-7, pp. 34-35. 
Tuomainen, L, Passi, S, Airaksinen, MSA, Juppo, A, Linden-Lahti, C 2010, 'Ajankohtaiskatsaus farmasian erikoistumiskoulutuksiin ja -
opintoihin Suomessa', Dosis, vol 26, no. 1, pp. 28-30. 
Westerling, A, Haikala, V, Hynninen, J, Airaksinen, MSA 2010, 'Tietojärjestelmiltä vaaditaan yhä enemmän', Apteekkari : Suomen 
apteekkarilehti, vol 99, no. 7-8, pp. 46-49. 
D2 Article in professional hand or guide book or in a professional data system, or text book 
material 
2010 
Kurko, T, Kentala , J, Mesiäislehto-Soukka , H, Sandström , P 2010, 'Terveydenhuollon ammattilaiset tupakasta vieroituksen tukena – 
tutkimuskatsaus', in P Sandström, A Leppänen, O Simonen (eds), Tupakasta vieroituksen organisointi ja käytännöt , Julkaisuja , 
no. 15, vol. 2009, Sosiaali- ja terveysministeriö, Helsinki , pp. 21-32. 
D4 Published development or research report 
2007 
Aaltonen, J, Aschan, H, Blom, M, Kaila, M, Komulainen, J, Savikurki, S 2007, Loppuraportti. HEALTHTECH-arviointi Tekes 2779/31/6, 
Helsinki. 
2008 
Terzibanjan, A, Laaksonen, R, Weiss, M, Airaksinen, MSA, Wuliji, T 2008, Medication Error Reporting Systems - Lessons Learnt: 
Executive Summary of the Findings, International Pharmaceutical Federation. 
2010 
EunetPas WP4 2010, GOOD MEDICATION SAFETY PRACTICES IN EUROPE: Transferability of good practices,. 
D5 Text book or professional handbook or guidebook or dictionary 
2005 
Airaksinen, M 2005, Hoitona lääke, Lähihoito, Edita, Helsinki. 
Wuliji, T, Airaksinen, M 2005, Counselling, concordance and communication: innovative education for pharmacists, IPFS. 
2007 
Alaranta, A, Hulmi, J, Mikkonen, J, Rossi, J, Mero, A (eds)  2007, Lääkkeet ja lisäravinteet urheilussa: suorituskykyyn ja kehon 
koostumukseen vaikuttavat aineet, Nutrimed Oy, Helsinki . 
E1 Popular article, newspaper article 
2005 
Airaksinen, M, Dahlström, A 2005, 'Hoitaja potilaan lääkehoidon toteuttajana', Hoitona lääke, pp. 16-35. 
2006 
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Pohjanoksa-Mäntylä, M, Varunki, M 2006, 'Psyykenlääkkeet ja psykiatria - haaste apteekeille', Semina : Suomen farmaseuttiliiton 
äänenkannattaja, vol 2006, no. 1, pp. 12-13. 
2008 
Airaksinen, M 2008, 'Tuhti annos lääkepolitiikkaa ja lihavuusongelmaa kahdessa uutuuskirjassa',  Dosis, vol 24, no. 4, pp. 334-335. 
Pohjanoksa-Mäntylä, M, Saari, J, Airaksinen, M, Bell, S 2008, 'Internet lääketiedon lähteenä: tutkimus masentuneiden tietotarpeista ja 
tiedonhausta', Vertainen: Mieli Maasta ry:n jäsentiedote, vol 2008, no. 4, pp. 13-15. 
Pohjanoksa-Mäntylä, M, Johanna, S, Ulla, N, Karjalainen, A, Pylkkänen, K, Airaksinen, MSA, Bell, S 2008, 'Use of the Internet for 
antidepressant drug information', Gamian-Europe Newsletter, vol 10, no. 31, pp. 14-15. 
E2 Popular monograph 
2009 
Airaksinen, MSA, Blom, M, Pohjanoksa-Mäntylä, M, Linden-Lahti, C, Kurko, T 2009, Farmakoterapian tilanneharjoituksia: Näyttöön 
perustuva asiakaspalvelu ja lääkeneuvonta, 7. painos edn, Farmasian opettajien ja tutkijoiden yhdistys ry, Helsinki. 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Marja Sisko Anneli Airaksinen ,  Marja Blom ,  Ville Aalto-Setälä, Marika Pohjanoksa-
Mäntylä ,  Simon Bell ,  Raisa Laaksonen ,  Maaret Mira Varunki , 
Katja Pitkä ,  Reijo Kärkkäinen ,  Carita Linden-Lahti ,  Heli 
Kansanaho, Antti Alaranta ,  Minna Väänänen , Kalle Jyri Mikael Aaltonen , Maarit 
Dimitrow, Anna-Riia Holmström , Sari Koski ,  Terhi Kurko ,  Saija Leikola , 
Stiina Parkkamäki ,  Sanna Passi ,  Juha Matias Sinnemäki , 
Kirsi Pietilä, Tuula Teinilä ,  Anna Westerling ,  
  
Activity type 
Supervisor or co-supervisor of doctoral thesis 24 
Prizes and awards 7 
Editor of research journal 2 
Peer review of manuscripts 26 
Editor of series 1 
Membership or other role in review committee 3 
Membership or other role in research network 1 
Membership or other role in national/international committee, council, board 50 
Membership or other role in public Finnish or international organization 20 
Membership or other role of body in private company/organisation 2 
Other tasks of an expert in private sector 4 
Participation in interview for written media 3 
Participation in radio programme 2 
Participation in TV programme 1 
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2 Listing of activities 2005-2010 
Supervisor or co-supervisor of doctoral thesis 
Marja Sisko Anneli Airaksinen ,  
Supervised Academic Dissertation, Completed in 2001, Marja Sisko Anneli Airaksinen, 2001  … 
Supervised Academic Dissertation, completed in 2003, Marja Sisko Anneli Airaksinen, 2003  … 
Supervised Academic Dissertation, completed in 2004, Marja Sisko Anneli Airaksinen, 2004  … 
Main supervisor, 10 doctoral dissertations in progress, Division of Social Pharmacy, University of Helsinki, Finland, Marja Sisko Anneli 
Airaksinen, 2005  2010 
Main supervisor, 2 doctoral dissertations completed in 2005, 2006, Department of Social Pharmacy, University of Kuopio, Finland, Marja 
Sisko Anneli Airaksinen, 2005  2006, Finland 
Main supervisor, 3 doctoral dissertations completed in 2006, 2008 and 2010, Division of Social Pharmacy, University of Helsinki, 
Finland, Marja Sisko Anneli Airaksinen, 2005  2010, Finland 
Supervised Academic Dissertation, completed in 2005, Marja Sisko Anneli Airaksinen, 2005  … 
Supervised Academic Dissertation, completed in 2005, Marja Sisko Anneli Airaksinen, 2005  … 
Supervisor, a doctoral dissertation completed in 2005, Division of Social Pharmacy, University of Helsinki, Finland, Marja Sisko Anneli 
Airaksinen, 2005  … 
Supervised Academic Dissertasion, completed in 2006, Marja Sisko Anneli Airaksinen, 2006  … 
Supervised Academic Dissertation, completed in 2006, Marja Sisko Anneli Airaksinen, 2006  … 
Supervised Academic Dissertation, completed in 2008, Marja Sisko Anneli Airaksinen, 2008  … 
Supervised Academic Dissertation, completed in 2010, Marja Sisko Anneli Airaksinen, 2010  … 
Marja Blom ,  
Supervisor of Doctoral Dissertation (Ph.D), Johanna Hirvonen, Marja Blom, 03.2003  12.2007, Finland 
Supervisor of Doctoral Dissertation (Ph.D), Outi Simonen, Marja Blom, 2005  …, Finland 
Supervisor of Doctoral Dissertation (Ph.D), Ulla Tuominen, Marja Blom, 2005  …, Finland 
Supervisor, Member of a Supervising Group Doctoral Dissertatio (Ph.D), Inger Mäenpää, Marja Blom, 2006  … 
Supervisor, Member of a Supervising Group, Doctoral Dissertatio (Ph.D), Maarit Virta-Helenius, Marja Blom, 2007  …, Finland 
Supervisor of Doctoral Dissertation (Ph.D), Kalle Aaltonen, Marja Blom, 2010  …, Finland 
Simon Bell ,  
Supervisor/Co-supervisor of PhD Student, Simon Bell, 2007  2010 
Suoervision/Co-supervision of PhD student, Simon Bell, 2008  2010, Estonia 
Raisa Laaksonen ,  
Development and evaluation of a competency framework for pharmacy undergraduate students to support their learning in professional 
practice, Raisa Laaksonen, 01.2008  …, United Kingdom 
Prevention of and learning from medication errors in healthcare, Raisa Laaksonen, 01.2008  …, Finland 
Prescribing in cardiovascular disease and role of the hospital pharmacist in the therapeutic management of the disease in Khartoum 
hospitals, Raisa Laaksonen, 09.2010  …, United Kingdom 
Prizes and awards 
Marja Sisko Anneli Airaksinen ,  
Award on the contribution to professional affairs. The Finnish Pharmacists’ Association, 2004., Marja Sisko Anneli Airaksinen, 2004  
… 
Marja Blom ,  
Science Award of Helsinki University Hospital, Jorvi Hospital 2006, Marja Blom, 2006, Finland 
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The best article in the International Journal of Technology Assessment in Health Care in 2005, Marja Blom, 2006 
Marika Pohjanoksa-Mäntylä ,  
Top reviewer 2007 / Research in Social and Administrative Pharmacy, Marika Pohjanoksa-Mäntylä, 2007 
Raisa Laaksonen ,  
Adjunct professorship, Raisa Laaksonen, 30.09.2010  …, Finland 
Honorary lectureship, Raisa Laaksonen, 01.10.2010  30.09.2013, United Kingdom 
Terhi Kurko ,  
Innopeli- prize of the faculty of Pharmacy, Terhi Kurko, 27.10.2010 
Editor of research journal 
Marja Sisko Anneli Airaksinen ,  
Member, advisory board, Research in Social and Administrative Pharmacy (April 2007 - present), Marja Sisko Anneli Airaksinen, 
04.2007  … 
Member, editorial board, Pharmacy Practice (March 2007- present), Marja Sisko Anneli Airaksinen, 03.2007  … 
Peer review of manuscripts 
Marja Sisko Anneli Airaksinen ,  
Peer reviewer in Dosis (Finnish Pharmaceutical Journal)., Marja Sisko Anneli Airaksinen, 1998  … 
Peer reviewer in Pharmacy World and Science, Marja Sisko Anneli Airaksinen, 2004  … 
Peer reviewer in Research in Social and Administrative Pharmacy, Marja Sisko Anneli Airaksinen, 2008  … 
Peer reviewer in British Medical Journal, Marja Sisko Anneli Airaksinen, 2009  … 
Peer reviewer in International Journal of Technology Assesment in Health Care, in 2010, Marja Sisko Anneli Airaksinen, 2010  … 
Marja Blom ,  
Reviewer, Marja Blom, 2005  2010, Finland 
Reviewer, Marja Blom, 2007  … 
Reviewer, Marja Blom, 2008  … 
Reviewer, Marja Blom, 2010  … 
Reviewer, Marja Blom, 2010  …, Finland 
Marika Pohjanoksa-Mäntylä ,  
Research in Social and Administrative Pharmacy, Marika Pohjanoksa-Mäntylä, 2007  … 
Dosis, Marika Pohjanoksa-Mäntylä, 2009  … 
Pharmacy World &amp; Science: International Journal of Clinical Pharmacy and Pharmaceutical Care, Marika Pohjanoksa-Mäntylä, 
2010  … 
Simon Bell ,  
British Journal of Clinical Pharmacology, Simon Bell, 2006  … 
Clinical Therapeutics, Simon Bell, 2006  … 
Drugs and Aging, Simon Bell, 2006  … 
European Journal of Clinical Pharmacology, Simon Bell, 2006  … 
Journal of Clinical Pharmacology, Simon Bell, 2006  … 
Psychiatric Services, Simon Bell, 2006  … 
Quality and Safety in Health Care, Simon Bell, 2006  … 
Schizoprhenia Research, Simon Bell, 2006  … 
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Raisa Laaksonen ,  
Pharmacy Education, Raisa Laaksonen, 2006  2008, United Kingdom 
International Journal of Pharmacy Practice, Raisa Laaksonen, 2008  …, United Kingdom 
American Journal of Pharmaceutical Education, Raisa Laaksonen, 2009  …, United States 
Pharmacy Education Journal, Raisa Laaksonen, 2010  … 
Pharmacy World &amp; Science, Raisa Laaksonen, 2010  … 
Editor of series 
Marja Sisko Anneli Airaksinen ,  
Member, editorial board, DOSIS - Finnish Pharmaceutical Journal, (January 1998 – December 2010), Marja Sisko Anneli Airaksinen, 
01.01.1998  31.12.2010 
Membership or other role in review committee 
Marja Sisko Anneli Airaksinen ,  
External reviewer, 3 promotions to senior positions (tenure track), 2004, 2005, 2010 University of Sydney, Australia., Marja Sisko Anneli 
Airaksinen, 2004  2010, Australia 
External reviewer, scientific report, National Insurance Institution 2005., Marja Sisko Anneli Airaksinen, 2005, Finland 
External reviewer, Professorship in Public Health, 2006, Nordic School of Public Health, Sweden., Marja Sisko Anneli Airaksinen, 2006, 
Sweden 
Membership or other role in research network 
Marja Sisko Anneli Airaksinen ,  
Member in International Pharmaceutical Federation 2000 – present, Marja Sisko Anneli Airaksinen, 2000  … 
Membership or other role in national/international committee, council, board 
Marja Sisko Anneli Airaksinen ,  
Member, Executive Committee, Pharmacy Information Section, International Pharmaceutical Federation (FIP), 2000 – 2008;, Marja 
Sisko Anneli Airaksinen, 01.01.2000  31.12.2008 
Chair; Working group for Guidelines for Good Patient Counseling Practice, a joint project with Pharmacy Information Section, 
International Pharmaceutical Federation (FIP) and International Pharmacy Student Federation (IPSF), 2002-2008., Marja Sisko Anneli 
Airaksinen, 2002  2008 
Council Member, Finnish Pharmacists’ Association, 1994-1997, 2002 – 2009., Marja Sisko Anneli Airaksinen, 2002  2009 
Chair, Expert Group on Safe Medication Practices under Expert Committee on Pharmaceutical Questions, Council of Europe 2004-
2006., Marja Sisko Anneli Airaksinen, 2004  2006 
Chair, Working Group on Internship Training, Faculty of Pharmacy, University of Helsinki, Marja Sisko Anneli Airaksinen, 2004  …, 
Finland 
Member, Coordination group of TIPPA Project, 2004-present., Marja Sisko Anneli Airaksinen, 2004  … 
Member, Council on Academic Affairs, Faculty of Pharmacy, University of Helsinki, Marja Sisko Anneli Airaksinen, 01.01.2004  
31.12.2009, Finland 
Member, Faculty Senate, Faculty of Pharmacy, University of Helsinki, Marja Sisko Anneli Airaksinen, 01.01.2004  31.12.2009, Finland 
Member, National Advisory Board, Professional Development studies in pharmacy practice, University of Helsinki and University of 
Kuopio, Finland, 2004-present., Marja Sisko Anneli Airaksinen, 2004  … 
Member, working group on safe medication practices, National Centre for Pharmacotherapy Development ROHTO, 2004-2009., Marja 
Sisko Anneli Airaksinen, 01.01.2004  31.12.2009 
Board member, Drug Discovery and Technology Center (DDTC), Faculty of Pharmacy, University of Helsinki, Marja Sisko Anneli 
Airaksinen, 01.01.2005  31.12.2005, Finland 
Board member, Pharmaceutical Learning Centre, 2005- 2008., Marja Sisko Anneli Airaksinen, 2005  2008 
Member, Working Group on Collaborative Practice, Board of Pharmaceutical Practice (BPP), International Pharmaceutical Federation 
(FIP), 2007-2008, Marja Sisko Anneli Airaksinen, 2007  2008 
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Member, Working Group on Information to Patients, Pharmaceutical Forum, European Commission, 2007-2008, Marja Sisko Anneli 
Airaksinen, 2007  2008 
Board member, Graduate School in Pharmaceutical Research, Marja Sisko Anneli Airaksinen, 2008  2009, Finland 
Chair, Working Group on Hospital Pharmacy Specialization Training, Marja Sisko Anneli Airaksinen, 2009  …, Finland 
Board member, Association of Patient Safety, (2010-present), Marja Sisko Anneli Airaksinen, 2010  … 
Chair, Council of Public Affairs, Faculty of Pharmacy, University of Helsinki, Marja Sisko Anneli Airaksinen, 2010  …, Finland 
Marja Blom ,  
Member, The Nordic Health Economists’ Study Group, Marja Blom, 1995  2011 
Member of executive committee, The Finnish Health Economist’s Society, Marja Blom, 2001  2007, Finland 
Member of executive committee, The Finnish Society of Social Medicine, Marja Blom, 2001  2007, Finland 
Member, The International Health Economics Association, iHEA, Marja Blom, 2001  2011, Canada 
Member, The Health Technology Assessment International, HTAi, Marja Blom, 2007  2011 
Vice President, The Finnish Health Economist’s Society, Marja Blom, 2007  2010, Finland 
Member in the organising committee of Helsinki Drug Research 2008, Marja Blom, 01.2008  06.2008, Finland 
Member, International Society for Pharmacoeconomics and Outcomes Research, ISPOR, Marja Blom, 2008  2011, United States 
Member in the local organising committee on the 8th European Conference on Health Economics 2010, Marja Blom, 2009  2010 
Member in the scientific programme committee of the 8th European Conference on Health Economics 2010, Marja Blom, 2009  2010 
Member of Judges for Poster and Podium Sessions in the ISPOR 12th Annual European Congress, Paris 2009, Marja Blom, 
25.10.2009  27.10.2009, United States 
Scientific reviewer in the International Research Review Committee of ISPOR 2nd Latin America Conference,, Marja Blom, 2009, United 
States 
Scientific reviewer in the International Research Review Committee of ISPOR in the 12th European Congress, Paris 2009, Marja Blom, 
2009, United States 
Scientific reviewer, the International Research Review Committee of ISPOR 14th Annual International Meeting, Marja Blom, 2009, 
United States 
Scientific reviewer in the International Research Review Committee in the 8th Conference on Health Economics 2010, Marja Blom, 
2010, Canada 
Marika Pohjanoksa-Mäntylä ,  
Pharmaceutical committee, Marika Pohjanoksa-Mäntylä, 2006  2009, Finland 
The board of the Pharmaceutical Learning Centre, Marika Pohjanoksa-Mäntylä, 2008, Finland 
The board of the Pharmaceutical Learning Centre, Marika Pohjanoksa-Mäntylä, 2009  …, Finland 
Pharmaceutical committee, Marika Pohjanoksa-Mäntylä, 2010  2013, Finland 
Simon Bell ,  
Pharmacy Practice, Simon Bell, 2006  … 
Research in Social and Administrative Pharmacy, Simon Bell, 2007  … 
Pharmacy World and Science (Now International Journal of Clinical Pharmacy), Simon Bell, 2009  … 
Raisa Laaksonen ,  
Academic Pharmacy Group, Raisa Laaksonen, 2007  …, United Kingdom 
The European Pharmaceutical Students' Association (EPSA) Board of Trustees, Raisa Laaksonen, 2007  …, Belgium 
The European Pharmaceutical Students' Association (EPSA) Steering Committee on Mapping the Competencies of the European 
Pharmacist, Raisa Laaksonen, 2007  2009, Belgium 
Pharmacy Days Symposium Organising Committee, Raisa Laaksonen, 01.2010  11.2011, Finland 
The European Association of Hospital Pharmacists (EAHP) Working Group, Raisa Laaksonen, 2010  …, Belgium 
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Katja Pitkä ,  
Opetusapteekkiharjoittelun kehittämistyöryhmä, Katja Pitkä, 2009  …, Finland 
Sairaala-apteekkiharjoittelun kehittämistyöryhmä, Katja Pitkä, 2010  …, Finland 
Terhi Kurko ,  
Suomen Apteekkariliiton savuttomuustyöryhmän jäsen, Terhi Kurko, 2005  … 
Saija Leikola ,  
TIPPA-coordination group, Saija Leikola, 2010  …, Finland 
The board of the Pharmaceutical Learning Centre, Saija Leikola, 2010  2011, Finland 
Membership or other role in public Finnish or international organization 
Marja Sisko Anneli Airaksinen ,  
Member of the Committee for Science, University of Helsinki, Marja Sisko Anneli Airaksinen, 01.01.2004  31.12.2006 
Member of the Committee of Academic Publishing, University of Helsinki, Marja Sisko Anneli Airaksinen, 2004  2006, Finland 
Member, working group on quality of geriatric pharmacotherapy, Ministry of Social Affairs and Health, 2006- 2009., Marja Sisko Anneli 
Airaksinen, 2006  2009 
Chair, Committee for Development of Doctoral Studies in University of Helsinki, Marja Sisko Anneli Airaksinen, 2007  2009, Finland 
Member of Committee of Academic Affairs in University of Helsinki, Marja Sisko Anneli Airaksinen, 2007  2009, Finland 
Permanent advisor, Steering Group on Patient Safety, Ministry of Social Affairs and Health, 2007- 2009., Marja Sisko Anneli Airaksinen, 
2007  2009 
Project Group on Academic Affairs, University Reform in University of Helsinki, Marja Sisko Anneli Airaksinen, 2008  2009, Finland 
Member in the project of Ministry of Social Affairs and Health, Marja Sisko Anneli Airaksinen, 2009  … 
Member, Working Group on Academic Leadership in University of Helsinki, Marja Sisko Anneli Airaksinen, 01.01.2009  31.12.2009 
University of Helsinki. Coordination committee for specialization trainings in industrial, hospital and community pharmacy sectors. 
Member (2009- ), Marja Sisko Anneli Airaksinen, 2009  … 
University of Helsinki. Steering group for specialization training in hospital pharmacy. Chair (2009-), Marja Sisko Anneli Airaksinen, 2009 
 … 
Member, Working Group on Pharmaceutical Policy 2020, Ministry of Social Affairs and Health (2010-present)., Marja Sisko Anneli 
Airaksinen, 2010  … 
Representative of FIP at the WHO Working Group on Patient Safety Curriculum Guide, a multidisciplinary version (2010 - present), 
Marja Sisko Anneli Airaksinen, 2010  … 
Vice Chair in Steering Committee for International Evaluation of Research in University of Helsinki, Marja Sisko Anneli Airaksinen, 2010 
 …, Finland 
Vice member, Board of Palmenia Centre for Continuing Education, Marja Sisko Anneli Airaksinen, 2010  …, Finland 
Marja Blom ,  
Expert member on Health Technology Assessment in The Finnish Office for Health Technology Assessment, 2007-2009, Marja Blom, 
2007  2009 
Eduskunnan sosiaali- ja terveysvaliokunta, kuulemistilaisuus 2.3.2010, Marja Blom, 02.03.2010, Finland 
Member of Expert Group of Pharmaceutical Pricing Board, Ministry of Social Affairs and Health, 2010-2013, Marja Blom, 01.01.2010  
31.12.2012, Finland 
Carita Linden-Lahti ,  
Farmasian erikoistumiskoulutusten yhteistyöverkosto, Carita Linden-Lahti, 01.2009  08.2010, Finland 
Farmasian tiedekunnan valintalautakunta, Carita Linden-Lahti, 01.2010  08.2010, Finland 
Membership or other role of body in private company/organisation 
Marja Sisko Anneli Airaksinen ,  
Member, Professional Board, Finnish Pharmacists’ Association; 1998-2005., Marja Sisko Anneli Airaksinen, 1998  2005 
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Member of the Board of the Helsinki University Pharmacy, Marja Sisko Anneli Airaksinen, 2007  …, Finland 
Other tasks of an expert in private sector 
Carita Linden-Lahti ,  
Farmasian Oppimiskeskuksen hallituksen varajäsen, Carita Linden-Lahti, 05.2009  05.2010, Finland 
Farmasian Päivien ohjelmatyöryhmä 2009, Carita Linden-Lahti, 01.2009  05.2009, Finland 
Osastofarmasian erityispätevyyden suunnittelutyöryhmä, Carita Linden-Lahti, 01.2009  08.2010, Finland 
Farmaseuttinen valiokunta, Carita Linden-Lahti, 01.2010  08.2010, Finland 
Participation in interview for written media 
Marika Pohjanoksa-Mäntylä ,  
Interview in a journal, Marika Pohjanoksa-Mäntylä, 20.09.2010, Finland 
Carita Linden-Lahti ,  
Haastattelu Aamulehteen, Carita Linden-Lahti, 01.11.2010  …, Finland 
Saija Leikola ,  
Interview at a magazine, Saija Leikola, 28.12.2009  …, Finland 
Participation in radio programme 
Marja Sisko Anneli Airaksinen ,  
Asiantuntijahaastattelu Yleisradiolle, Marja Sisko Anneli Airaksinen, 06.10.2010 
Carita Linden-Lahti ,  
Haastattelu sairaalafarmasiasta, Carita Linden-Lahti, 03.2010  …, France 
Participation in TV programme 
Marja Sisko Anneli Airaksinen ,  
Asiantuntijana Kipulääkkeet ruokakauppoihin. A-talk –keskusteluohjelma, Marja Sisko Anneli Airaksinen, 16.02.2007 
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Airaksinen M 
Basic statistics 
Number of publications (P)  56 
Number of citations (TCS) 175 
Number of citations per publication (MCS)   3.30 
Percentage of uncited publications 34% 
Field-normalized number of citations per publication (MNCS)    .90 
Field-normalized average journal impact (MNJS)    .82 
Field-normalized proportion highly cited publications (top 10%)    .67 
Internal coverage    .65 
 
Trend analyses 
 
MNCS 
 
THCP10 
 
MNJS 
Collaboration 
 
Performance (MNCS) by collaboration type 
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by CWTS, Leiden University, the Netherlands 
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